29 September 2025 - The list price will be consistent with the US to reflect the value of the innovation.

AbbVie today announced plans to launch Elahere (mirvetuximab soravtansine-gynx) in the UK at a list price equal to the US, reflecting the advanced innovation and value of the treatment for adult patients with folate receptor-alpha positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

Read AbbVie press release